Abstract 298P
Background
Cervical Cancer is one of the leading causes of cancer mortality in Indian women.Most of the women present in advanced stages of cervical cancer. Although CTRT remains the standard of care there were several challenges in implementation. In this study we assesed 3-year outcomes of LACC patients and the factors impacted the outcome.
Methods
We retrospectively analysed the records and follow up data of 131 patients of locally advanced cervical cancer registered in 2019. We noted the baseline characteristics include demographic data, comorbidities, histology and stage, treatment details, follow up data which include their disease status, death. Table: 298P
Baseline characterstics
| Variables | N=131 | (%) | |
| Comorbidities | |||
| Diabetes Mellitus | 19 | 14.5 | |
| Hypertension | 18 | 13.7 | |
| Others | 16 | 12.2 | |
| None | 78 | 59.5 | |
| ECOG | |||
| 1 | 98 | 74.8 | |
| 2 | 29 | 22.1 | |
| 3 | 4 | 3.1 | |
| Histology | |||
| Squamous Cell Carcinoma | 121 | 92.4 | |
| Adenocarcinoma | 6 | 4.6 | |
| Others | 4 | 3.1 | |
| Stage (FIGO 2018) | |||
| IB | 8 | 6.1 | |
| IIA | 5 | 3.8 | |
| IIB | 47 | 35.9 | |
| IIIA | 6 | 4.6 | |
| IIIB | 47 | 35.9 | |
| IIIC1 | 9 | 6.9 | |
| IIIC2 | 3 | 2.3 | |
| IVA | 6 | 4.6 |
Results
The median follow-up time was 45.5 months (IQR - 39.7-47.4). 5 patients had defaulted radiotherapy, 5 defaulted brachytherapy and 9 deferred brachytherapy. The average time from diagnosis to start of treatment is 109 days. 3-year OS was 78.6%. Stage-wise survival was IB (100%), IIA (100%), IIB (78.7%), IIIA (83.3%), IIIB (78.7%), IIIC (66.6%) & IVA (50%). 82.4% in CTRT patients and 72.4% in RT alone were alive. Dose >85Gy resulted in better local control and survival. The 3-year OS of patients with Overall Treatment Time <56 days is 89.1% while OTT >56 days is 80.7% (p=0.215).
Conclusions
The findings of this study highlighted the importance of concurrent chemoradiation in locally advanced cervical cancer. Doses >85 Gy to the disease and OTT <56 days showed better outcomes. Strategies to improve compliance to CTRT and image-guided adaptive brachytherapy will help in improved local control and survival. In low-middle income countries, these outcomes are also impacted by non-compliance and long wait-list to treatment, which is often due to logistical and socio-cultural barriers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract